|
|
|
|
 |
CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Company's Shares |
| Companies mentioned in this article: |
|
CardioDynamics |
|
| 3/12/2008 @ 7:15 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ impedance cardiography (ICG) technology, today announced that its Board of Directors has approved a resolution proposing a reverse split of 1 for 7 shares of the Company's common stock. The proposed reverse split is expected to become effective, subject to shareholder approval, shortly after the Company's May 8, 2008, Annual Shareholders Meeting.
In the reverse split, each seven (7) shares of CardioDynamics common stock issued and outstanding will be combined into one (1) share of common stock, which initially should have the effect of proportionately increasing the stock price. Following the reverse split, the total number of shares outstanding will be reduced to approximately 7.2 million shares. Additionally, the reverse split will affect all shares of CardioDynamics common stock proportionally, including its Convertible Notes and outstanding stock options.
Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "Recently, a number of our largest shareholders have expressed overwhelming support to affect a reverse split to maintain our Nasdaq listing and attract a greater level of interest among investors and analysts. We also believe the reverse split comes at an excellent time and is complementary with the positive turnaround occurring in our business. Not only do we think the capital structure, post-reverse split, will be more attractive to potential investors, but our recent four consecutive quarters of revenue growth, international sales momentum, continued growth plan for 2008, and intense focus on achieving positive operating cash flow by the fourth quarter of 2008, should all be positive catalysts for new investors."
In November, 2007, the Company transferred to the Nasdaq Capital Market and has until April 14, 2008, to maintain a minimum bid price of $1.00 per share for 10 or more consecutive days in order to meet the continued listing requirements. The Company anticipates receiving a notice of noncompliance in April, 2008, and if so, will request a hearing with Nasdaq to present its plan to achieve compliance which will include the intention to seek prompt shareholder approval of the reverse stock split.
About CardioDynamics:
CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ ICG products. The Company's BioZ ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at www.cdic.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, October 3, 2008 |
 |
|
Essentialis Announces Two Presentations at Upcoming Conferences Posted 6:19 AM PST
|
| |
| Thursday, October 2, 2008 |
|
|
SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis Posted 1:08 PM PST
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain Posted 10:41 AM PST
|
| |
| Wednesday, October 1, 2008 |
|
|
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel Posted 6:07 PM PST
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society Posted 6:04 PM PST
University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia Posted 3:52 PM PST
BioMed Realty Trust Announces Public Offering of 7,500,000 Shares of Common Stock Posted 3:51 PM PST
SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. Posted 3:48 PM PST
Halozyme Therapeutics to Host Research Day for Investors and Analysts Posted 3:46 PM PST
Bio-Matrix Scientific Group, Inc. Receives and Processes First Cord Blood Specimens as Part of the Company’s Quality Assurance Program Posted 7:15 AM PST
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference Posted 4:33 AM PST
|
| |
| Tuesday, September 30, 2008 |
|
|
Genoptix Announces Participation at the Second Annual William Blair Small Cap Growth Conference Posted 10:15 AM PST
Cytori Receives Key Patent for its Cosmetic & Reconstructive Surgery Product Posted 7:54 AM PST
|
| |
| Monday, September 29, 2008 |
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference Posted 4:46 PM PST
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting Posted 8:43 AM PST
Bio-Quant Announces the Expansion of Its Research Animal Diagnostic Services to Cover All Nine Species Posted 8:27 AM PST
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer Posted 8:09 AM PST
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008 Posted 7:44 AM PST
|
| |
| Thursday, September 25, 2008 |
|
|
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds Posted 9:18 AM PST
CytRx Corporation to Present New Data from Its Proprietary Molecular Chaperone Drug Discovery Technology at the San Diego LEADS Meeting Posted 8:55 AM PST
Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Posted 7:53 AM PST
|
| |
| Wednesday, September 24, 2008 |
|
|
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients Posted 3:09 PM PST
ChemBridge Corporation Enters Into New Discovery Chemistry Strategic Alliance With AstraZeneca Posted 6:40 AM PST
|
| |
| Tuesday, September 23, 2008 |
|
|
Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes Posted 4:37 PM PST
Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing Posted 2:54 PM PST
Ebioscience Expands Multicolor Cellular Analysis Portfolio With Introduction of eFluor Brand and Commercial Launch of eFluor Nanocrystal Product Line Posted 8:52 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
